Abstract
Abstract The selective BCL-2 antagonist venetoclax has recently demonstrated striking efficacy in patients with CLL, even those with high risk, refractory disease. This presentation will review the preclinical data that supported exploring BCL-2 inhibition in CLL and the clinical trial results of venetoclax monotherapy in this disease. Tumor lysis syndrome and how this risk can be mitigated will also be discussed. Mitochondrial priming reflects the proximity of a cell to the threshold of apoptosis and can be measured using a functional technique known as BH3 profiling. Data will also be presented which suggest that BH3 profiling may serve as a predictive biomarker of response to venetoclax in CLL, and that the change in priming in response to ex vivo drug treatments may help identify optimal combination partners for venetoclax to inform the design of clinical trials for CLL patients. Citation Format: Matthew S. Davids. Targeting Bcl-2 as a therapeutic strategy and predictive biomarker in CLL. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr SY16-03.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
